APA (7th ed.) Citation

B, M., J, H., D, M., S, B., L, M., TMP, H., . . . AD, S. (2023). Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic oncology, 172, 65. https://doi.org/10.1016/j.ygyno.2023.03.009

Chicago Style (17th ed.) Citation

B, McNamara, et al. "Uterine Leiomyosarcomas Harboring MAP2K4 Gene Amplification Are Sensitive in Vivo to PLX8725, a Novel MAP2K4 Inhibitor." Gynecologic Oncology 172 (2023): 65. https://doi.org/10.1016/j.ygyno.2023.03.009.

MLA (9th ed.) Citation

B, McNamara, et al. "Uterine Leiomyosarcomas Harboring MAP2K4 Gene Amplification Are Sensitive in Vivo to PLX8725, a Novel MAP2K4 Inhibitor." Gynecologic Oncology, vol. 172, 2023, p. 65, https://doi.org/10.1016/j.ygyno.2023.03.009.